We are live on ! Find out more
VLC

Van Leeuwen & Company Portfolio holdings

AUM $197M
1-Year Est. Return 44.16%
This Fund
S&P 500
This Quarter Est. Return
+10.45%
1 Year Est. Return
+44.16%
3 Year Est. Return
+75.42%
5 Year Est. Return
+199.79%
10 Year Est. Return
AUM
$159M
AUM Growth
+$10.4M
Cap. Flow
-$1.99M
Cap. Flow %
-1.25%
Top 10 Hldgs %
43.29%
Holding
83
New
11
Increased
18
Reduced
41
Closed
7

Top Sells

Rank Stock Value
1
ABBV icon
AbbVie
ABBV
+$3.05M
2
NEE icon
NextEra Energy
NEE
+$1.42M
3
TMO icon
Thermo Fisher Scientific
TMO
+$1.13M
4
MSCI icon
MSCI
MSCI
+$997K
5
AON icon
Aon
AON
+$906K

Sector Composition

Rank Sector Weight
1 Technology 17.24%
2 Healthcare 13.36%
3 Consumer Discretionary 12.42%
4 Financials 9.9%
5 Communication Services 9.77%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
ING icon
76
ING
ING
$102B
$168K 0.11%
12,300
ABBV icon
77
AbbVie
ABBV
$435B
-19,155
Closed -$3.05M
AON icon
78
Aon
AON
$76B
-2,872
Closed -$906K
CFG icon
79
Citizens Financial Group
CFG
$30.6B
-27,496
Closed -$835K
IBB icon
80
iShares Biotechnology ETF
IBB
$9.77B
-1,551
Closed -$200K
MSCI icon
81
MSCI
MSCI
$40.9B
-1,782
Closed -$997K
NEE icon
82
NextEra Energy
NEE
$177B
-18,459
Closed -$1.42M
UBER icon
83
Uber
UBER
$153B
-9,900
Closed -$314K

Similar funds

Van Leeuwen & Company's Q2 2023 Portfolio in Review

As of Q2 2023, Van Leeuwen & Company held 83 positions worth $159M, up 7% from $149M the previous quarter. Its ten largest holdings account for 43% of the portfolio.

Van Leeuwen & Company's Q2 2023 filing shows 11 new, 18 increased, 41 reduced and 7 closed positions. Its largest new stake was DexCom: 15,579 shares worth $1.98M. The largest sale was AbbVie, an estimated $3.05M.

By sector, the portfolio is most concentrated in Technology at 17% of assets, up from 15% a quarter earlier, followed by Healthcare and Consumer Discretionary.

  • Van Leeuwen & Company's largest Q2 2023 buy was DexCom: 15,579 shares worth $1.98M.
  • Van Leeuwen & Company added most to State Street Energy Select Sector SPDR ETF in Q2 2023, an estimated $1.72M increase.
  • Van Leeuwen & Company's biggest Q2 2023 reduction was Thermo Fisher Scientific, cutting an estimated $1.13M.
  • Van Leeuwen & Company fully exited AbbVie in Q2 2023, selling an estimated $3.05M.
  • Van Leeuwen & Company's ten largest holdings make up 43% of its $159M portfolio in Q2 2023.
  • Van Leeuwen & Company opened 11 new positions and closed 7 in Q2 2023.
  • Van Leeuwen & Company's portfolio value rose 7% quarter-over-quarter to $159M.

Based on Van Leeuwen & Company's 13F filing for Q2 2023, filed 7 Aug 2023.